Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• International guidelines advocate optimizing medical therapy before ICD implantation in severe left ventricular dysfunction.
• Suboptimal use of ACE inhibitors (ACE-i) and beta-blockers impacts ICD shock-free survival, SCD, and mortality.
• Limited data exist on the effect of angiotensin receptor blockers (ARBs) on SCD in heart failure (HF) patients.

Purpose of the Study:

• To systematically analyze the impact of ARBs on SCD in HF.
• To review the renin-angiotensin system's (RAS) role in cardiac electrical remodeling and arrhythmic substrates.
• To evaluate ARBs as a tool for improving survival and reducing SCD risk in HF.

Main Methods:

• Systematic analysis of existing literature on ARBs and SCD in HF.
• Review of studies investigating the RAS's contribution to electrical remodeling.
• Evaluation of evidence supporting RAS blockade for reducing SCD risk.

Main Results:

• The RAS is implicated as a critical component in the electrical remodeling of the failing myocardium.
• RAS blockade is associated with a reduced risk of SCD.
• High-dose ARBs may improve overall survival and reduce SCD risk through optimal AT1-receptor blockade.

Conclusions:

• ARBs are a potential therapeutic strategy for managing SCD risk in HF patients.
• Effective RAS blockade, particularly with high-dose ARBs, is key to improving outcomes.
• Further research is warranted to fully elucidate the role of ARBs in preventing SCD in HF.